Bjarne Bogen (born 18 January 1951) is a Norwegian immunologist, inventor and physician. He is widely known for his research on

DNA vaccines A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response. DNA vaccines work by injecting genetically engineered plasmid containing the D ...

, autoimmune disorders and

cancer immunology Cancer immunology is an interdisciplinary branch of biology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises ...

Career

Bogen graduated with a medical degree from the

University of Oslo The University of Oslo ( no, Universitetet i Oslo; la, Universitas Osloensis) is a public research university located in Oslo, Norway. It is the highest ranked and oldest university in Norway. It is consistently ranked among the top universit ...

in 1977. In the following two years, he completed his internship at Sandnessjøen hospital and in the municipalities of Lurøy and

Træna Træna is a municipality in Nordland county, Norway. It is part of the Helgeland traditional region. The administrative centre of the municipality is the island/village of Husøya. Other population centres include Selvær and Sanna. Fishing i ...

at the coastline of northern Norway.University of Oslo: Bjarne Bogen
/ref> In 1984, at the

University of Tromsø The University of Tromsø – The Arctic University of Norway (Norwegian: ''Universitetet i Tromsø – Norges arktiske universitet''; Northern Sami: ''Romssa universitehta – Norgga árktalaš universitehta'') is a state university in Norway an ...

he defended his PhD thesis entitled "Murine Th and B Lymphocyte Recognition of Isologous Immunoglobulin". Since 1986, Bogen has been working at the Institute for Clinical Medicine at the

, first as an

associate professor Associate professor is an academic title with two principal meanings: in the North American system and that of the ''Commonwealth system''. Overview In the ''North American system'', used in the United States and many other countries, it is a ...

before becoming full professor in 1993. In 1991, he was authorized as a specialist in clinical immunology, and has since 1995 had a part-time position as a senior consultant at the

Oslo University Hospital Oslo University Hospital ( no, Oslo universitetssykehus; OUS) is a university hospital in Oslo, Norway. With over 24,000 employees it is List of hospitals by staff, the largest hospital organization in Europe. It is affiliated with the University o ...

. He was director of the KG Jebsen Centre for Influenza Vaccine Research (JIV) from 2013 to 2019. During his scientific career, Bogen has been a guest researcher at the Basel Institute for Immunology (1985–87),

Stanford University Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. The campus occupies , among the largest in the United States, and enrolls over 17,000 students. Stanford is consider ...

(1996–97),

Dana–Farber Cancer Institute Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana–Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated b ...

(2004–05) and The Scripps Research Institute (2005, 2019–20).Vaccibody company: Scientific Advisor

Bogen is a fellow of the

Norwegian Academy of Science and Letters The Norwegian Academy of Science and Letters ( no, Det Norske Videnskaps-Akademi, DNVA) is a learned society based in Oslo, Norway. Its purpose is to support the advancement of science and scholarship in Norway. History The Royal Frederick Univer ...

since 2007. From 1997 to 2019, he was a member of the Editorial Board for Scandinavian Journal of Immunology and from 2005 to 2007 for the journal Hematologica. Throughout his career, he has supervised 27 PhD-students, along with 23 students enrolled in either MSc or MD-PhD student programs. In 2018, Bogen became an honorary Member of the Norwegian Society for Immunology. In 2020 he was awarded the

King Olav V Olav V (; born Prince Alexander of Denmark; 2 July 1903 – 17 January 1991) was the King of Norway from 1957 until his death in 1991. Olav was the only child of King Haakon VII of Norway and Maud of Wales. He became heir apparent to the Norw ...

Cancer Research Prize by the Norwegian Cancer Society for his work within cancer immunology and his contribution to development of personalized cancer vaccines (Vaccibody), as well as the Innovation Price of the

for his research on

Research

Throughout his career, Bogen has published more than 220 scientific papers, among them in scientific journals such as Cell,

Immunity Immunity may refer to: Medicine * Immunity (medical), resistance of an organism to infection or disease * ''Immunity'' (journal), a scientific journal published by Cell Press Biology * Immune system Engineering * Radiofrequence immunity desc ...

, Nature Biotechnology and

Nature Communications ''Nature Communications'' is a peer-reviewed, open access, scientific journal published by Nature Portfolio since 2010. It is a multidisciplinary journal and it covers the natural sciences, including physics, chemistry, earth sciences, medicine, ...

.Weiss S, Bogen B. (1991) MHC class II-restricted presentation of intracellular antigen. Cell. Feb 22;64(4):767-76. Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. (2011) Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.Lunde E, Munthe LA, Vabø A, Sandlie I, Bogen B. (1999) Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol. Jul;17(7):670-5.Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity. Mar;22(3):371-83. In the early 1990s, Bogen and co-workers discovered a new type of collaboration between T and

B-cells B cells, also known as B lymphocytes, are a type of white blood cell of the lymphocyte subtype. They function in the humoral immunity component of the adaptive immune system. B cells produce antibody molecules which may be either secreted or ...

( Idiotype-driven T-B collaboration)Weiss S, Bogen B. (1989) B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci Jan;86(1):282-6. Munthe LA, Os A, Zangani M, Bogen B. (2004) MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol. Jun 15;172(12):7476-84. and how such collaboration can, under unfortunate circumstances, lead to the development of autoimmune disordersMunthe LA, Corthay A, Os A, Zangani M, Bogen B. (2005) Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol. Aug 15;175(4):2391-400. and B cell lymphomas.Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B. (2007) Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med. May 14;204(5):1181–91. Epub 2007 May 7. In another vein of research, Bogen et al. demonstrated that

CD4 In molecular biology, CD4 (cluster of differentiation 4) is a glycoprotein that serves as a co-receptor for the T-cell receptor (TCR). CD4 is found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic ...

T-cells, in collaboration with macrophages, can kill cancer cells such as multiple myeloma cells in an antitumor immune response.Lauritzsen GF, Weiss S, Dembic Z, Bogen B. (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A. Jun 7;91(12):5700-4.Dembic Z, Schenck K, Bogen B. (2000) Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A. Mar 14;97(6):2697-702. Bogen has received the Senior Research Award from the U.S. Multiple Myeloma Research Foundation (2002, 2004 and 2008). In yet another direction of research, Bogen and co-workers have developed new types of vaccine molecules known as Troybodys (Medinnova prize 1998) and VaccibodiesFredriksen AB, Bogen B. (2007) Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood. Sep 15;110(6):1797-805. Epub 2007 May 31. (Medinnova prize 2003). Vaccibodies have been developed as preclinical DNA vaccines for infectious diseases such as

influenza Influenza, commonly known as "the flu", is an infectious disease caused by influenza viruses. Symptoms range from mild to severe and often include fever, runny nose, sore throat, muscle pain, headache, coughing, and fatigue. These symptoms ...

as well as for different types of cancers.Fredriksen AB, Sandlie I, Bogen B. (2006) DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther. Apr;13(4):776-85. Epub 2006 Jan 18. The biotech company Vaccibody AS was founded by Bogen and co-workers in 2007.

Teaching

During the last 30 years, Bogen has given lectures for medical students and physicians in basic and clinical immunology. From 1998 to 2013, he was the Head of Studies of Immunology at the Faculty of Medicine, University of Oslo. In 2000, he published the textbook "Immunologi" (''English: "Immunology"'') together with professor Ludvig A. Munthe,Universitetsforlaget: «Imunologi�

/ref> for which they received the TanoAschehoug's-prize.

References

{{DEFAULTSORT:Bogen, Bjarne 1951 births Living people Norwegian immunologists University of Oslo alumni Academic staff of the University of Oslo Members of the Norwegian Academy of Science and Letters